Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 106

1.

Clinical-scale selection and viral transduction of human naïve and central memory CD8+ T cells for adoptive cell therapy of cancer patients.

Casati A, Varghaei-Nahvi A, Feldman SA, Assenmacher M, Rosenberg SA, Dudley ME, Scheffold A.

Cancer Immunol Immunother. 2013 Oct;62(10):1563-73. doi: 10.1007/s00262-013-1459-x. Epub 2013 Aug 1.

2.

Human effector CD8+ T cells derived from naive rather than memory subsets possess superior traits for adoptive immunotherapy.

Hinrichs CS, Borman ZA, Gattinoni L, Yu Z, Burns WR, Huang J, Klebanoff CA, Johnson LA, Kerkar SP, Yang S, Muranski P, Palmer DC, Scott CD, Morgan RA, Robbins PF, Rosenberg SA, Restifo NP.

Blood. 2011 Jan 20;117(3):808-14. doi: 10.1182/blood-2010-05-286286. Epub 2010 Oct 22.

3.

Phenotypic and functional attributes of lentivirus-modified CD19-specific human CD8+ central memory T cells manufactured at clinical scale.

Wang X, Naranjo A, Brown CE, Bautista C, Wong CW, Chang WC, Aguilar B, Ostberg JR, Riddell SR, Forman SJ, Jensen MC.

J Immunother. 2012 Nov-Dec;35(9):689-701. doi: 10.1097/CJI.0b013e318270dec7.

4.

A simplified method for the clinical-scale generation of central memory-like CD8+ T cells after transduction with lentiviral vectors encoding antitumor antigen T-cell receptors.

Yang S, Dudley ME, Rosenberg SA, Morgan RA.

J Immunother. 2010 Jul-Aug;33(6):648-58. doi: 10.1097/CJI.0b013e3181e311cb.

PMID:
20551831
5.

Marked anti-tumor effects of CD8(+)CD62L(+) T cells from melanoma-bearing mice.

Liao Y, Geng P, Tian Y, Miao H, Liang H, Zeng R, Ni B, Ruan Z.

Immunol Invest. 2015;44(2):147-63. doi: 10.3109/08820139.2014.944980. Epub 2014 Aug 14.

PMID:
25122543
6.

Human effector T cells derived from central memory cells rather than CD8(+)T cells modified by tumor-specific TCR gene transfer possess superior traits for adoptive immunotherapy.

Wu F, Zhang W, Shao H, Bo H, Shen H, Li J, Liu Y, Wang T, Ma W, Huang S.

Cancer Lett. 2013 Oct 10;339(2):195-207. doi: 10.1016/j.canlet.2013.06.009. Epub 2013 Jun 18.

PMID:
23791878
7.
8.

HLA-peptide multimer selection of adenovirus-specific T cells for adoptive T-cell therapy.

Chakupurakal G, Onion D, Bonney S, Cobbold M, Mautner V, Moss P.

J Immunother. 2013 Oct;36(8):423-31. doi: 10.1097/CJI.0b013e3182a8029e.

PMID:
23994889
9.

Adoptively transferred effector cells derived from naive rather than central memory CD8+ T cells mediate superior antitumor immunity.

Hinrichs CS, Borman ZA, Cassard L, Gattinoni L, Spolski R, Yu Z, Sanchez-Perez L, Muranski P, Kern SJ, Logun C, Palmer DC, Ji Y, Reger RN, Leonard WJ, Danner RL, Rosenberg SA, Restifo NP.

Proc Natl Acad Sci U S A. 2009 Oct 13;106(41):17469-74. doi: 10.1073/pnas.0907448106. Epub 2009 Sep 24.

11.

MART-1-specific melanoma tumor-infiltrating lymphocytes maintaining CD28 expression have improved survival and expansion capability following antigenic restimulation in vitro.

Li Y, Liu S, Hernandez J, Vence L, Hwu P, Radvanyi L.

J Immunol. 2010 Jan 1;184(1):452-65. doi: 10.4049/jimmunol.0901101. Epub 2009 Nov 30.

12.

Understanding the biology of ex vivo-expanded CD8 T cells for adoptive cell therapy: role of CD62L.

Díaz-Montero CM, Zidan AA, Pallin MF, Anagnostopoulos V, Salem ML, Wieder E, Komanduri K, Montero AJ, Lichtenheld MG.

Immunol Res. 2013 Dec;57(1-3):23-33. doi: 10.1007/s12026-013-8456-1.

PMID:
24218360
13.

Mimicking homeostatic proliferation in vitro generates T cells with high anti-tumor function in non-lymphopenic hosts.

Kaiser AD, Gadiot J, Guislain A, Blank CU.

Cancer Immunol Immunother. 2013 Mar;62(3):503-15. doi: 10.1007/s00262-012-1350-1. Epub 2012 Sep 23.

PMID:
23001162
14.

Transient stimulation expands superior antitumor T cells for adoptive therapy.

Kagoya Y, Nakatsugawa M, Ochi T, Cen Y, Guo T, Anczurowski M, Saso K, Butler MO, Hirano N.

JCI Insight. 2017 Jan 26;2(2):e89580. doi: 10.1172/jci.insight.89580.

16.

Tumor-Specific Effector CD8+ T Cells That Can Establish Immunological Memory in Humans after Adoptive Transfer Are Marked by Expression of IL7 Receptor and c-myc.

Chandran SS, Paria BC, Srivastava AK, Rothermel LD, Stephens DJ, Kammula US.

Cancer Res. 2015 Aug 15;75(16):3216-26. doi: 10.1158/0008-5472.CAN-15-0584. Epub 2015 Jun 22.

17.

T cell receptor (TCR) gene transfer with lentiviral vectors allows efficient redirection of tumor specificity in naive and memory T cells without prior stimulation of endogenous TCR.

Circosta P, Granziero L, Follenzi A, Vigna E, Stella S, Vallario A, Elia AR, Gammaitoni L, Vitaggio K, Orso F, Geuna M, Sangiolo D, Todorovic M, Giachino C, Cignetti A.

Hum Gene Ther. 2009 Dec;20(12):1576-88. doi: 10.1089/hum.2009.117.

PMID:
19678763
18.

Robust Identification of Suitable T-Cell Subsets for Personalized CMV-Specific T-Cell Immunotherapy Using CD45RA and CD62L Microbeads.

Mangare C, Tischer-Zimmermann S, Riese SB, Dragon AC, Prinz I, Blasczyk R, Maecker-Kolhoff B, Eiz-Vesper B.

Int J Mol Sci. 2019 Mar 20;20(6). pii: E1415. doi: 10.3390/ijms20061415.

19.

Decreased effector memory CD45RA+ CD62L- CD8+ T cells and increased central memory CD45RA- CD62L+ CD8+ T cells in peripheral blood of rheumatoid arthritis patients.

Maldonado A, Mueller YM, Thomas P, Bojczuk P, O'Connors C, Katsikis PD.

Arthritis Res Ther. 2003;5(2):R91-6. Epub 2003 Jan 6.

20.

Enhanced local and systemic anti-melanoma CD8+ T cell responses after memory T cell-based adoptive immunotherapy in mice.

Contreras A, Sen S, Tatar AJ, Mahvi DA, Meyers JV, Srinand P, Suresh M, Cho CS.

Cancer Immunol Immunother. 2016 May;65(5):601-11. doi: 10.1007/s00262-016-1823-8. Epub 2016 Mar 24.

Supplemental Content

Support Center